{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T03:09:41Z","timestamp":1787454581007,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ejogrb.2018.01.002","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T02:24:02Z","timestamp":1515464642000},"page":"75-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Does vaginal estriol make urodynamic changes in women with overactive bladder syndrome and genitourinary syndrome of menopause?"],"prefix":"10.1016","volume":"222","author":[{"given":"Maria Grazia","family":"Matarazzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Giunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sarpietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cianci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2018.01.002_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00192-009-0976-9","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"21","author":"Haylen","year":"2010","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0010","doi-asserted-by":"crossref","first-page":"138895","DOI":"10.1111\/j.1464-410X.2008.07601.x","article-title":"The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study","volume":"101","author":"Coyne","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0015","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1464-410X.1980.tb03058.x","article-title":"Third report on the standardization of terminology of lower urinary tract function","volume":"52","author":"International Continence Society","year":"1980","journal-title":"Br J Urol"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0020","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0025","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.maturitas.2014.07.013","article-title":"Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women\u2019s Sexual Health and The North American Menopause Society","volume":"79","author":"Portman","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0030","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1086\/515209","article-title":"Factors contributing to susceptibility of postmenopausal women to recurrent urinary tract infections","volume":"28","author":"Stamm","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0035","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0040","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0022-5347(17)43588-9","article-title":"Progesterone receptors in the female lower urinary tract","volume":"138","author":"Batra","year":"1987","journal-title":"J Urol"},{"issue":"4 Pt 2","key":"10.1016\/j.ejogrb.2018.01.002_bib0045","first-page":"722","article-title":"Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee","volume":"92","author":"Cardozo","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0050","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/gme.0b013e3181d0f6b9","article-title":"Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society","volume":"17","author":"The North American Menopause Society","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0055","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/gme.0b013e31805170eb","article-title":"The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society","volume":"14","author":"The North American Menopause Society","year":"2007","journal-title":"Menopause"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/GME.0000000000000485","article-title":"Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel","volume":"23","author":"Caruso","year":"2016","journal-title":"Menopause"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/nau.20583","article-title":"Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome","volume":"28","author":"Tseng","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0070","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/SPV.0000000000000256","article-title":"Combined tolterodine and vaginal estradiol cream for overactive bladder symptoms after randomized single-therapy treatment","volume":"22","author":"Ellington","year":"2016","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0075","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.urology.2015.01.002","article-title":"Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder","volume":"85","author":"Matsukawa","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0080","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.urology.2006.02.042","article-title":"Symptom assessment tool for overactive bladder syndrome\u2014overactive bladder symptom score","volume":"68","author":"Homma","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0085","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0895-4356(98)00107-3","article-title":"The factor structure of the SF-36 health survey in 10 countries: results from the IQOLA project: international quality of life assessment","volume":"51","author":"Ware","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/nau.10066","article-title":"Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies","volume":"21","author":"Sch\u00e4fer","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0095","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1464-410X.2012.11023.x","article-title":"Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience","volume":"110","author":"Wagg","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0100","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/bju.12649","article-title":"Phase III, randomized, double-blind, placebo controlled study of the b3-adrenoceptoragonist mirabegron, 50\u202fmg once-daily, in Japanese patients with overactive bladder","volume":"113","author":"Yamaguchi","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0105","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.tjog.2012.06.001","article-title":"Clinical and urodynamic effects of tolterodine in women with an overactive bladder","volume":"52","author":"Wang","year":"2013","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0110","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1447-0756.2010.01493.x","article-title":"Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome","volume":"37","author":"Hsiao","year":"2011","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0115","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/j.1442-2042.2010.02602.x","article-title":"Urodynamic effects of solifenacinin untreated female patients with symptomatic overactive bladder","volume":"17","author":"Tanaka","year":"2010","journal-title":"Int J Urol"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0120","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/GME.0000000000000851","article-title":"Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse","volume":"24","author":"Caruso","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0125","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00192-012-1891-z","article-title":"Urethral sphincter innervation and clitoral blood flow after the transobturator (TOT) approach","volume":"24","author":"Matarazzo","year":"2013","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.ejogrb.2018.01.002_bib0130","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00192-011-1364-9","article-title":"TOT does not affect the urethral sphincter innervation: a pilot study","volume":"22","author":"Caruso","year":"2011","journal-title":"Int Urogynecol J"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211518300022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211518300022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T19:27:00Z","timestamp":1721330820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211518300022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":26,"alternative-id":["S0301211518300022"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2018.01.002","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does vaginal estriol make urodynamic changes in women with overactive bladder syndrome and genitourinary syndrome of menopause?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2018.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}